Buchumschlag

ARAP1‐AS1 Overexpression Increases Diffuse Large B Cell Lymphoma Progression by Sponging miR‐508–5p to Activate the EMP1‐PI3K/AKT Pathway

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Yamei Chen, Minmin Ren, Lei Zhu, Ting Sun, Xiaoyong Wang, Lingling Jiang, Linlin Zhou, Dongyun Gao
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	Hematological Oncology
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Upregulated miR‐29a‐3p Prevent Malignant Features of Lymphoma Cells by Targeting MCL1
von: Tengfei Shi, et al.
Veröffentlicht: (2025)

Knockdown of VDAC1 Promotes Ferroptosis in Diffuse Large B‐Cell Lymphoma
von: Chuanming Lin, et al.
Veröffentlicht: (2025)

81 | REPRESSION OF miR‐29 VIA MYC LEADS TO INCREASED CD40 SIGNALING IN TRANSFORMED FOLLICULAR LYMPHOMA (FL) AND UNFAVOURABLE PROGNOSIS IN FL
von: D. Filip, et al.
Veröffentlicht: (2025)

RETRACTION: Burkitt Lymphoma Versus Diffuse Large B‐Cell Lymphoma: A Practical Approach
Veröffentlicht: (2026)

508 | BAYESIAN PENALIZED LIKELIHOOD RECONSTRUCTION ALGORITHM RESULTS IN SIMILAR PROGNOSTIC MARKERS ON FDG PET/CT IN DLBCL
von: H. L. Huang, et al.
Veröffentlicht: (2025)

A Novel Prognostic Score for Disease Progression and Mortality in Patients With Newly Diagnosed Primary Large B‐Cell Lymphoma of Immune‐Privileged Sites
von: Ganggang Wang, et al.
Veröffentlicht: (2025)

Peripheral T‐Cell Lymphoma: What's Next?
von: Sang Eun Yoon, et al.
Veröffentlicht: (2025)

Current Status of Revisions to the Lugano Classification in Lymphoma
Veröffentlicht: (2025)

UMG1 Defines a Targetable Subset of T‐Cell Lymphomas and Enables Precision Immunotherapy With a First‐in‐Class CD3ε Bispecific Engager
von: Daniele Caracciolo, et al.
Veröffentlicht: (2026)

Clinicopathological Characteristics of Extranodal Marginal Zone Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT‐Lymphoma) of the Intestine: A Single Center Analysis
von: Oskar Steinbrecher, et al.
Veröffentlicht: (2024)

Genetic and Transcriptomic Profiles Identify Potential Therapeutic Targets of Concurrent Follicular and Diffuse Large B‐Cell Lymphoma and Transformed Follicular Lymphoma
von: Rui Sun, et al.
Veröffentlicht: (2026)

Differential Expression of CD79B, CD19, and PD‐L1 in de Novo and Transformed CD20‐Negative Large B‐Cell Lymphomas
von: Yuto Kaimi, et al.
Veröffentlicht: (2026)

Follicular Lymphoma: Current Therapeutic Landscape and Future Prospects
von: Emil Kumar, et al.
Veröffentlicht: (2025)

Lomustine, Etoposide and Cyclophosphamide as Conditioning for Auto‐HCT in Lymphomas
von: Rafaella Cabral Samico, et al.
Veröffentlicht: (2025)

Breaking Traditions: Evaluating Single Fraction Radiation in Indolent Lymphoma
von: Hazim S. Ababneh, et al.
Veröffentlicht: (2024)

Nodular Lymphocyte‐Predominant Hodgkin Lymphoma: Update on Biology and Treatment
von: Peter Borchmann, et al.
Veröffentlicht: (2025)

Review of the Management of Relapsed/Refractory Follicular Lymphoma: An Italian Perspective
von: Giacomo Loseto, et al.
Veröffentlicht: (2025)

Indolent T‐Cell Lymphoma of the Gastrointestinal Tract Associated With Strongyloides Stercoralis Infection
von: Yue Zhao, et al.
Veröffentlicht: (2025)

Marginal Zone Lymphoma: Treatment Update With a Focus on Systemic Approaches
von: Sonali M. Smith
Veröffentlicht: (2025)

Discovery Science highlights from the 17th International Conference on Malignant Lymphoma
von: Gabriela Forestieri, et al.
Veröffentlicht: (2024)

Advancing Mantle Cell Lymphoma Risk Assessment: Navigating a Moving Target
von: Simone Ferrero, et al.
Veröffentlicht: (2025)

Evaluation of participation and recruitment bias in a prospective Real World Data in Lymphoma and Survival in Adults (REALYSA) cohort for newly diagnosed lymphoma patients over 1 year in a hematology department of teaching hospital
von: Caroline Le Lan, et al.
Veröffentlicht: (2024)

Ibrutinib With Bendamustine and Rituximab for Treatment of Patients With Relapsed/Refractory Aggressive B‐Cell Lymphoma
von: Meirav Kedmi, et al.
Veröffentlicht: (2024)

A SWOT‐Consensus for CAR‐T in Follicular Lymphoma: Fine Tuning of Patient Journey and Selection
von: Monia Marchetti, et al.
Veröffentlicht: (2025)

Molecular Features of Diffuse Large B‐Cell Lymphoma Associated With Primary Treatment Resistance
von: Allison M. Bock, et al.
Veröffentlicht: (2024)

Causal Associations of Gut Microbiota Species With Lymphoma: A Two‐Sample Mendelian Randomization Study
von: Mei Li, et al.
Veröffentlicht: (2025)

Late Cardiac Toxicity After Anthracyclines and Radiotherapy for Lymphoma—A Regression Analysis of Dose‐Response
von: Lotte Nygård, et al.
Veröffentlicht: (2025)

MerTK is Ectopically Expressed and Affects the Biological Function in Diffuse Large B‐Cell Lymphoma
von: Yan Li, et al.
Veröffentlicht: (2025)

Impact of Body Composition on Treatment Toxicity and Outcomes in Patients With Primary Mediastinal Large B‐Cell Lymphoma
von: Juliette Penichoux, et al.
Veröffentlicht: (2025)

Exploratory Analysis of Practical Predictive Indices for the Efficacy of Mogamulizumab in Patients With Aggressive Adult T‐Cell Leukemia‐Lymphoma
von: Yutaka Shimazu, et al.
Veröffentlicht: (2025)

Toxicity and Tolerability of the OEPA/COPDAC Regimen in Children and Adolescents With Hodgkin Lymphoma: A Real‐World Experience
von: Hala Bekhit, et al.
Veröffentlicht: (2025)

Adaptation and Performance of the Self‐Report‐Generated Charlson Comorbidity Index in the Lymphoma Epidemiology of Outcomes (LEO) Cohort
von: James R. Cerhan, et al.
Veröffentlicht: (2025)

Trends in Incidence and Survival of Patients With Primary Effusion Lymphoma in the United States: A Population Based Cohort Study
von: John L. Vaughn, et al.
Veröffentlicht: (2026)

Lifetime Treatment Trajectories of Mantle Cell Lymphoma: Simulation Based Analysis of 20 Years of Real‐World Data
von: Minna Harmanen, et al.
Veröffentlicht: (2025)

Changes in Lean Muscle Mass, Muscle Strength, and Physical Performance Following First‐Line Chemotherapy in Patients With Lymphoma
von: Charlotte Nørregaard Grønset, et al.
Veröffentlicht: (2025)

International Cost‐Effectiveness Analysis of Nivolumab Versus Brentuximab Vedotin for Patients With Advanced‐Stage Classic Hodgkin's Lymphoma
von: Youwen Zhu, et al.
Veröffentlicht: (2026)

Impact of Age on Biology, Presentation and Outcomes in Marginal Zone Lymphoma: Results From a Multicenter Cohort Study
von: Pallawi Torka, et al.
Veröffentlicht: (2025)

Outcomes of Bridging Therapy in Patients With Relapsed/Refractory Large B Cell Lymphoma Receiving Third‐Line CAR T
von: Inna Y. Gong, et al.
Veröffentlicht: (2026)

Post‐CAR T‐Cell Therapy Failure Metabolic Parameters Predict Survival and Response in Large B‐Cell Lymphoma
von: Hazim S. Ababneh, et al.
Veröffentlicht: (2024)

First Line Therapy in Mantle Cell Lymphoma—The Role of BTKi in the Initial Treatment of Transplant‐Eligible and ‐Ineligible Patients
von: E. Silkenstedt, et al.
Veröffentlicht: (2025)